-
公开(公告)号：US20070287667A1
公开(公告)日：2007-12-13
申请号：US11789377
申请日：2007-04-23
CPC分类号： C07K16/1009 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/565
摘要： Chimpanzee monoclonal antibodies and antigen binding fragments including a γ1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.
摘要翻译： 本文公开了黑猩猩单克隆抗体和包含结合甲型肝炎病毒（HAV）抗原的γ1链CDR3区域的抗原结合片段。 抗体中和HAV。 还公开了在检测甲型肝炎病毒中使用这些抗体和抗原结合片段的方法，用甲型肝炎病毒抑制受试者的感染，以及筛选影响HAV的药剂。
-
2.发明申请Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus 有权丙型肝炎病毒的主要中和位点，以及在接种方法中使用该中和部位和筛选中和乙型肝炎病毒抗体的方法公开(公告)号：US20050233316A1
公开(公告)日：2005-10-20
申请号：US11054041
申请日：2005-02-09
IPC分类号： A61K38/00 , A61K39/00 , C07K14/08 , C07K16/10 , C12Q1/70 , C07H21/04 , C07K14/02 , C07K16/08 , C12N5/06 , C12N15/86
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/505 , A61K2039/53 , C07K16/10 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C12N2770/28122
摘要： The invention describes the identification of a major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isolation and characterization of neutralizing chimpanzee monoclonal antibodies reactive to the neutralization site and the use of these antibodies in the diagnosis, treatment and prevention of HEV.
摘要翻译： 本发明描述了乙型肝炎病毒（HEV）的主要中和位点的鉴定以及该中和位点在接种方法中的用途以及筛选HEV中和抗体的方法。 本发明还描述了对中和黑素族中和位点反应的中和黑猩猩单克隆抗体的分离和表征以及这些抗体在HEV的诊断，治疗和预防中的用途。
-
3.发明授权Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus 有权丙型肝炎病毒的主要中和位点，以及在接种方法中使用该中和部位和筛选中和乙型肝炎病毒抗体的方法公开(公告)号：US07148323B2
公开(公告)日：2006-12-12
申请号：US11054041
申请日：2005-02-09
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/505 , A61K2039/53 , C07K16/10 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C12N2770/28122
摘要： The invention describes the identification of a major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isolation and characterization of neutralizing chimpanzee monoclonal antibodies reactive to the neutralization site and the use of these antibodies in the diagnosis, treatment and prevention of HEV.
摘要翻译： 本发明描述了乙型肝炎病毒（HEV）的主要中和位点的鉴定以及该中和位点在接种方法中的用途以及筛选HEV中和抗体的方法。 本发明还描述了对中和黑素族中和位点反应的中和黑猩猩单克隆抗体的分离和表征以及这些抗体在HEV的诊断，治疗和预防中的用途。
-
4.发明授权Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus 失效丙型肝炎病毒的主要中和位点，以及在接种方法中使用该中和部位和筛选中和乙型肝炎病毒抗体的方法公开(公告)号：US06930176B2
公开(公告)日：2005-08-16
申请号：US10148737
申请日：2000-11-30
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/505 , A61K2039/53 , C07K16/10 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C12N2770/28122
摘要： The invention describes the identification of major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isolation and characterization of neutralizing chimpanzee monoclonal antibodies reactive to the neutralization site and the use of these antibodies in the diagnosis, treatment and prevention of HEV.
摘要翻译： 本发明描述了乙型肝炎病毒（HEV）的主要中和位点的鉴定和该中和位点在接种方法中的用途以及筛选HEV中和抗体的方法。 本发明还描述了对中和黑素族中和位点反应的中和黑猩猩单克隆抗体的分离和表征以及这些抗体在HEV的诊断，治疗和预防中的用途。
-
5.发明授权Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C virus and their use in the diagnosis, treatment, and prevention of hepatitis C 失效肝细胞C病毒E2糖蛋白特异性单克隆抗体及其在丙型肝炎诊断，治疗和预防中的应用公开(公告)号：US06924362B2
公开(公告)日：2005-08-02
申请号：US10432006
申请日：2001-11-30
IPC分类号： A61K39/395 , A61P1/16 , A61P31/12 , C07K16/08 , C07K16/10 , C07K16/42 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/576 , G01N33/577 , G01N33/68 , C07K16/00 , A61K39/42 , C12Q1/70 , G01N33/53
CPC分类号： G01N33/6878 , A61K2039/505 , C07K16/109 , C07K16/4216 , C07K2317/21 , C07K2317/55 , C07K2317/565 , G01N33/5767 , G01N2333/18
摘要： The present invention describes the identification and characterization of five human HC E1-specific monoclonal antibodies isolated from a phage display library and their use in the diagnosis, treatment, and prevention of HCV in mammals, preferably humans.
摘要翻译： 本发明描述了从噬菌体展示文库分离的五种人HC E1特异性单克隆抗体的鉴定和鉴定及其在哺乳动物，优选人类中诊断，治疗和预防HCV的用途。
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
